TrialThe oncologist2016
A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
Manish A Shah et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
70 papers cite itlatest 60 shown
this paperpooled ittrialcites it